A pan-cancer landscape of telomeric content shows that RAD21 and HGF alterations are associated with longer telomeres
Background Cancer cells can proliferate indefinitely through telomere maintenance mechanisms. These mechanisms include telomerase-dependent elongation, mediated by TERT activation, and alternative lengthening of telomeres (ALT), linked to loss of ATRX or DAXX . Methods We analyzed the telomeric cont...
Saved in:
Published in | Genome medicine Vol. 14; no. 1; pp. 25 - 15 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
London
BioMed Central
26.02.2022
BioMed Central Ltd BMC |
Subjects | |
Online Access | Get full text |
ISSN | 1756-994X 1756-994X |
DOI | 10.1186/s13073-022-01029-7 |
Cover
Abstract | Background
Cancer cells can proliferate indefinitely through telomere maintenance mechanisms. These mechanisms include telomerase-dependent elongation, mediated by
TERT
activation, and alternative lengthening of telomeres (ALT), linked to loss of
ATRX
or
DAXX
.
Methods
We analyzed the telomeric content of 89,959 tumor samples within the Foundation Medicine dataset and investigated the genomic determinants of high telomeric content, linking them to clinical outcomes, when available.
Results
Telomeric content varied widely by disease type with leiomyosarcoma having the highest and Merkel cell carcinoma having the lowest telomeric content. In agreement with previous studies, telomeric content was significantly higher in samples with alterations in
TERC
,
ATRX,
and
DAXX
. We further identified that amplifications in two genes,
RAD21
and
HGF
, were enriched in samples with high telomeric content, which was confirmed using the PCAWG/ICGC dataset. We identified the minimal amplified region associated with high telomeric content for
RAD21
(8q23.1–8q24.12), which excludes
MYC
, and for
HGF
(7q21.11). Our results demonstrated that
RAD21
and
HGF
exerted an additive telomere lengthening effect on samples with existing alterations in canonical genes previously associated with telomere elongation. Furthermore, patients with breast cancer who harbor
RAD21
alterations had poor median overall survival and trended towards higher levels of Ki-67 staining.
Conclusions
This study highlights the importance of the role played by
RAD21
(8q23.1–8q24.12) and
HGF
(7q21.11) in the lengthening of telomeres, supporting unlimited replication in tumors. These findings open avenues for work aimed at targeting this crucial pathway in tumorigenesis. |
---|---|
AbstractList | Cancer cells can proliferate indefinitely through telomere maintenance mechanisms. These mechanisms include telomerase-dependent elongation, mediated by TERT activation, and alternative lengthening of telomeres (ALT), linked to loss of ATRX or DAXX.
We analyzed the telomeric content of 89,959 tumor samples within the Foundation Medicine dataset and investigated the genomic determinants of high telomeric content, linking them to clinical outcomes, when available.
Telomeric content varied widely by disease type with leiomyosarcoma having the highest and Merkel cell carcinoma having the lowest telomeric content. In agreement with previous studies, telomeric content was significantly higher in samples with alterations in TERC, ATRX, and DAXX. We further identified that amplifications in two genes, RAD21 and HGF, were enriched in samples with high telomeric content, which was confirmed using the PCAWG/ICGC dataset. We identified the minimal amplified region associated with high telomeric content for RAD21 (8q23.1-8q24.12), which excludes MYC, and for HGF (7q21.11). Our results demonstrated that RAD21 and HGF exerted an additive telomere lengthening effect on samples with existing alterations in canonical genes previously associated with telomere elongation. Furthermore, patients with breast cancer who harbor RAD21 alterations had poor median overall survival and trended towards higher levels of Ki-67 staining.
This study highlights the importance of the role played by RAD21 (8q23.1-8q24.12) and HGF (7q21.11) in the lengthening of telomeres, supporting unlimited replication in tumors. These findings open avenues for work aimed at targeting this crucial pathway in tumorigenesis. Background Cancer cells can proliferate indefinitely through telomere maintenance mechanisms. These mechanisms include telomerase-dependent elongation, mediated by TERT activation, and alternative lengthening of telomeres (ALT), linked to loss of ATRX or DAXX. Methods We analyzed the telomeric content of 89,959 tumor samples within the Foundation Medicine dataset and investigated the genomic determinants of high telomeric content, linking them to clinical outcomes, when available. Results Telomeric content varied widely by disease type with leiomyosarcoma having the highest and Merkel cell carcinoma having the lowest telomeric content. In agreement with previous studies, telomeric content was significantly higher in samples with alterations in TERC, ATRX, and DAXX. We further identified that amplifications in two genes, RAD21 and HGF, were enriched in samples with high telomeric content, which was confirmed using the PCAWG/ICGC dataset. We identified the minimal amplified region associated with high telomeric content for RAD21 (8q23.1-8q24.12), which excludes MYC, and for HGF (7q21.11). Our results demonstrated that RAD21 and HGF exerted an additive telomere lengthening effect on samples with existing alterations in canonical genes previously associated with telomere elongation. Furthermore, patients with breast cancer who harbor RAD21 alterations had poor median overall survival and trended towards higher levels of Ki-67 staining. Conclusions This study highlights the importance of the role played by RAD21 (8q23.1-8q24.12) and HGF (7q21.11) in the lengthening of telomeres, supporting unlimited replication in tumors. These findings open avenues for work aimed at targeting this crucial pathway in tumorigenesis. Keywords: Telomere, Tumor, RAD21, HGF, Breast, TERC, TERT, ATRX, DAXX, ALT Background Cancer cells can proliferate indefinitely through telomere maintenance mechanisms. These mechanisms include telomerase-dependent elongation, mediated by TERT activation, and alternative lengthening of telomeres (ALT), linked to loss of ATRX or DAXX . Methods We analyzed the telomeric content of 89,959 tumor samples within the Foundation Medicine dataset and investigated the genomic determinants of high telomeric content, linking them to clinical outcomes, when available. Results Telomeric content varied widely by disease type with leiomyosarcoma having the highest and Merkel cell carcinoma having the lowest telomeric content. In agreement with previous studies, telomeric content was significantly higher in samples with alterations in TERC , ATRX, and DAXX . We further identified that amplifications in two genes, RAD21 and HGF , were enriched in samples with high telomeric content, which was confirmed using the PCAWG/ICGC dataset. We identified the minimal amplified region associated with high telomeric content for RAD21 (8q23.1–8q24.12), which excludes MYC , and for HGF (7q21.11). Our results demonstrated that RAD21 and HGF exerted an additive telomere lengthening effect on samples with existing alterations in canonical genes previously associated with telomere elongation. Furthermore, patients with breast cancer who harbor RAD21 alterations had poor median overall survival and trended towards higher levels of Ki-67 staining. Conclusions This study highlights the importance of the role played by RAD21 (8q23.1–8q24.12) and HGF (7q21.11) in the lengthening of telomeres, supporting unlimited replication in tumors. These findings open avenues for work aimed at targeting this crucial pathway in tumorigenesis. Cancer cells can proliferate indefinitely through telomere maintenance mechanisms. These mechanisms include telomerase-dependent elongation, mediated by TERT activation, and alternative lengthening of telomeres (ALT), linked to loss of ATRX or DAXX.BACKGROUNDCancer cells can proliferate indefinitely through telomere maintenance mechanisms. These mechanisms include telomerase-dependent elongation, mediated by TERT activation, and alternative lengthening of telomeres (ALT), linked to loss of ATRX or DAXX.We analyzed the telomeric content of 89,959 tumor samples within the Foundation Medicine dataset and investigated the genomic determinants of high telomeric content, linking them to clinical outcomes, when available.METHODSWe analyzed the telomeric content of 89,959 tumor samples within the Foundation Medicine dataset and investigated the genomic determinants of high telomeric content, linking them to clinical outcomes, when available.Telomeric content varied widely by disease type with leiomyosarcoma having the highest and Merkel cell carcinoma having the lowest telomeric content. In agreement with previous studies, telomeric content was significantly higher in samples with alterations in TERC, ATRX, and DAXX. We further identified that amplifications in two genes, RAD21 and HGF, were enriched in samples with high telomeric content, which was confirmed using the PCAWG/ICGC dataset. We identified the minimal amplified region associated with high telomeric content for RAD21 (8q23.1-8q24.12), which excludes MYC, and for HGF (7q21.11). Our results demonstrated that RAD21 and HGF exerted an additive telomere lengthening effect on samples with existing alterations in canonical genes previously associated with telomere elongation. Furthermore, patients with breast cancer who harbor RAD21 alterations had poor median overall survival and trended towards higher levels of Ki-67 staining.RESULTSTelomeric content varied widely by disease type with leiomyosarcoma having the highest and Merkel cell carcinoma having the lowest telomeric content. In agreement with previous studies, telomeric content was significantly higher in samples with alterations in TERC, ATRX, and DAXX. We further identified that amplifications in two genes, RAD21 and HGF, were enriched in samples with high telomeric content, which was confirmed using the PCAWG/ICGC dataset. We identified the minimal amplified region associated with high telomeric content for RAD21 (8q23.1-8q24.12), which excludes MYC, and for HGF (7q21.11). Our results demonstrated that RAD21 and HGF exerted an additive telomere lengthening effect on samples with existing alterations in canonical genes previously associated with telomere elongation. Furthermore, patients with breast cancer who harbor RAD21 alterations had poor median overall survival and trended towards higher levels of Ki-67 staining.This study highlights the importance of the role played by RAD21 (8q23.1-8q24.12) and HGF (7q21.11) in the lengthening of telomeres, supporting unlimited replication in tumors. These findings open avenues for work aimed at targeting this crucial pathway in tumorigenesis.CONCLUSIONSThis study highlights the importance of the role played by RAD21 (8q23.1-8q24.12) and HGF (7q21.11) in the lengthening of telomeres, supporting unlimited replication in tumors. These findings open avenues for work aimed at targeting this crucial pathway in tumorigenesis. Cancer cells can proliferate indefinitely through telomere maintenance mechanisms. These mechanisms include telomerase-dependent elongation, mediated by TERT activation, and alternative lengthening of telomeres (ALT), linked to loss of ATRX or DAXX. We analyzed the telomeric content of 89,959 tumor samples within the Foundation Medicine dataset and investigated the genomic determinants of high telomeric content, linking them to clinical outcomes, when available. Telomeric content varied widely by disease type with leiomyosarcoma having the highest and Merkel cell carcinoma having the lowest telomeric content. In agreement with previous studies, telomeric content was significantly higher in samples with alterations in TERC, ATRX, and DAXX. We further identified that amplifications in two genes, RAD21 and HGF, were enriched in samples with high telomeric content, which was confirmed using the PCAWG/ICGC dataset. We identified the minimal amplified region associated with high telomeric content for RAD21 (8q23.1-8q24.12), which excludes MYC, and for HGF (7q21.11). Our results demonstrated that RAD21 and HGF exerted an additive telomere lengthening effect on samples with existing alterations in canonical genes previously associated with telomere elongation. Furthermore, patients with breast cancer who harbor RAD21 alterations had poor median overall survival and trended towards higher levels of Ki-67 staining. This study highlights the importance of the role played by RAD21 (8q23.1-8q24.12) and HGF (7q21.11) in the lengthening of telomeres, supporting unlimited replication in tumors. These findings open avenues for work aimed at targeting this crucial pathway in tumorigenesis. Abstract Background Cancer cells can proliferate indefinitely through telomere maintenance mechanisms. These mechanisms include telomerase-dependent elongation, mediated by TERT activation, and alternative lengthening of telomeres (ALT), linked to loss of ATRX or DAXX. Methods We analyzed the telomeric content of 89,959 tumor samples within the Foundation Medicine dataset and investigated the genomic determinants of high telomeric content, linking them to clinical outcomes, when available. Results Telomeric content varied widely by disease type with leiomyosarcoma having the highest and Merkel cell carcinoma having the lowest telomeric content. In agreement with previous studies, telomeric content was significantly higher in samples with alterations in TERC, ATRX, and DAXX. We further identified that amplifications in two genes, RAD21 and HGF, were enriched in samples with high telomeric content, which was confirmed using the PCAWG/ICGC dataset. We identified the minimal amplified region associated with high telomeric content for RAD21 (8q23.1–8q24.12), which excludes MYC, and for HGF (7q21.11). Our results demonstrated that RAD21 and HGF exerted an additive telomere lengthening effect on samples with existing alterations in canonical genes previously associated with telomere elongation. Furthermore, patients with breast cancer who harbor RAD21 alterations had poor median overall survival and trended towards higher levels of Ki-67 staining. Conclusions This study highlights the importance of the role played by RAD21 (8q23.1–8q24.12) and HGF (7q21.11) in the lengthening of telomeres, supporting unlimited replication in tumors. These findings open avenues for work aimed at targeting this crucial pathway in tumorigenesis. |
ArticleNumber | 25 |
Audience | Academic |
Author | Albacker, Lee A. Frampton, Garrett M. Hopkins, Julia F. Song, Jiarong Sharaf, Radwa Montesion, Meagan |
Author_xml | – sequence: 1 givenname: Radwa surname: Sharaf fullname: Sharaf, Radwa organization: Foundation Medicine Inc – sequence: 2 givenname: Meagan surname: Montesion fullname: Montesion, Meagan organization: Foundation Medicine Inc – sequence: 3 givenname: Julia F. surname: Hopkins fullname: Hopkins, Julia F. organization: Foundation Medicine Inc – sequence: 4 givenname: Jiarong surname: Song fullname: Song, Jiarong organization: Foundation Medicine Inc – sequence: 5 givenname: Garrett M. surname: Frampton fullname: Frampton, Garrett M. organization: Foundation Medicine Inc – sequence: 6 givenname: Lee A. orcidid: 0000-0002-5070-1783 surname: Albacker fullname: Albacker, Lee A. email: lalbacker@foundationmedicine.com organization: Foundation Medicine Inc |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35227290$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kkuLFDEUhQsZcR76B1xIQBA3NVZSqVSyEZrRecCAIAruwq3kVnea6kqbpBz896YfDt0iQxYJyXfOTXLPeXEy-hGL4jWtLimV4kOkddXWZcVYWdGKqbJ9VpzRthGlUvzHycH6tDiPcVlVgjPevihO64axlqnqrJhmZA1jaWA0GMgAo40G1kh8TxIOfoXBGWL8mHBMJC78QyRpAYl8nX1ilGSc3N5cExgSBkjOj5FAQAIxeuMgoSUPLi3I4Md5tt87YnxZPO9hiPhqP18U368_f7u6Le-_3Nxdze5LI2iVSsqUsAyBU8PBdtxKJaFjhlO0RholLWBngStslagppVUjpWLYmb7pKtHUF8Xdztd6WOp1cCsIv7UHp7cbPsw1hOTMgFr0HWcAjDY9cAQLhtdNowQ2VkLT2Oz1cee1nrpVrp8_JMBwZHp8MrqFnvtfWkpZC6mywfu9QfA_J4xJr1w0OORPRz9FzUTNJVeCsYy-3aFzyFdzY--zo9ngeiZyQ7OjrDN1-R8qD4srl3uGvcv7R4J3B4IF5rYtoh-mbeOOwTeHb3185N_cZIDtABN8jAH7R4RWehNOvQunzuHU23DqNovkPyLj0jY1-d5ueFpa76Qx19lkSS_9FMacnadUfwBA2Pi- |
CitedBy_id | crossref_primary_10_1038_s41598_023_38923_y crossref_primary_10_1371_journal_pone_0272707 crossref_primary_10_1038_s41525_023_00369_6 crossref_primary_10_1089_dna_2023_0331 |
Cites_doi | 10.18632/oncotarget.16961 10.1038/nm1197-1271 10.1093/nar/gkq929 10.1038/nature02118 10.1016/j.febslet.2010.06.009 10.1038/s41388-019-0872-9 10.1038/415530a 10.1038/sj.bjc.6603110 10.1126/science.1200609 10.1186/s13073-017-0424-2 10.1038/s41598-019-56847-4 10.1038/ng.3781 10.1016/0092-8674(89)90035-4 10.1186/s12859-019-2851-0 10.1210/jc.2008-0372 10.1016/S0959-8049(97)00062-2 10.1111/1475-6773.13669 10.1038/emboj.2012.266 10.1093/carcin/bgh296 10.1177/0300891620910805 10.1101/gr.125567.111 10.1096/fj.08-108985 10.1186/bcr3176 10.1038/onc.2013.103 10.1038/sj.onc.1205058 10.1002/gcc.10289 10.1006/excr.2001.5446 10.20892/j.issn.2095-3941.2016.0066 10.1139/g89-104 10.1074/jbc.M002843200 10.1186/gb-2012-13-12-r113 10.1158/1078-0432.CCR-08-0099 10.1038/nsmb.2245 10.1016/j.ymthe.2017.12.015 10.1093/hmg/10.18.1945 10.1016/j.ajpath.2012.10.001 10.1371/journal.pgen.1002772 10.1038/nbt.2696 10.1038/s41586-020-1969-6 10.1016/j.ajpath.2011.06.018 10.1128/MCB.21.12.3862-3875.2001 10.1158/1535-7163.MCT-04-0241 10.1016/j.cell.2011.02.013 10.1038/s41467-019-13824-9 10.1016/j.exger.2008.01.005 10.1001/jama.2019.3241 10.1038/bjc.2014.31 10.3390/genes11121442 10.1126/science.1207313 10.1186/bcr2814 10.1016/j.ajhg.2015.12.021 10.5152/ejbh.2019.4778 10.1126/science.7605428 |
ContentType | Journal Article |
Copyright | The Author(s) 2022 2022. The Author(s). COPYRIGHT 2022 BioMed Central Ltd. |
Copyright_xml | – notice: The Author(s) 2022 – notice: 2022. The Author(s). – notice: COPYRIGHT 2022 BioMed Central Ltd. |
DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM DOA |
DOI | 10.1186/s13073-022-01029-7 |
DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: C6C name: Springer Nature OA Free Journals url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Biology |
EISSN | 1756-994X |
EndPage | 15 |
ExternalDocumentID | oai_doaj_org_article_6fb42aa215fa4eadac435596e5d8a55d PMC8883689 A699488383 35227290 10_1186_s13073_022_01029_7 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- 0R~ 2WC 53G 5VS 7X7 88E 8FE 8FH 8FI 8FJ AAFWJ AAJSJ AASML ABDBF ABUWG ACGFS ACJQM ACUHS ADUKV AENEX AFKRA AFPKN AHBYD AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AOIAM BBNVY BENPR BHPHI BMC BPHCQ BVXVI C6C CCPQU DIK E3Z EBD EBLON EBS ESX FYUFA GROUPED_DOAJ GX1 HCIFZ HMCUK HYE IAO IHR IHW INH INR ITC KQ8 LK8 M1P M7P MK0 M~E O5R O5S OK1 PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PQGLB PQQKQ PROAC PSQYO PUEGO RBZ ROL RPM RSV SBL SOJ TUS UKHRP AAYXX ALIPV CITATION CGR CUY CVF ECM EIF NPM PMFND 7X8 5PM |
ID | FETCH-LOGICAL-c610t-1296d2ea41c4adb4d898ab2c41edc8c98daebda49e7963111058892ebcf5b0653 |
IEDL.DBID | DOA |
ISSN | 1756-994X |
IngestDate | Wed Aug 27 01:00:44 EDT 2025 Thu Aug 21 18:24:41 EDT 2025 Fri Sep 05 05:07:17 EDT 2025 Tue Jun 17 21:35:03 EDT 2025 Tue Jun 10 20:08:40 EDT 2025 Thu May 22 21:21:37 EDT 2025 Thu Apr 03 07:08:22 EDT 2025 Tue Jul 01 04:01:11 EDT 2025 Thu Apr 24 23:11:15 EDT 2025 Sat Sep 06 07:28:02 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | DAXX TERT TERC RAD21 HGF ATRX Breast Tumor ALT Telomere |
Language | English |
License | 2022. The Author(s). Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c610t-1296d2ea41c4adb4d898ab2c41edc8c98daebda49e7963111058892ebcf5b0653 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0002-5070-1783 |
OpenAccessLink | https://doaj.org/article/6fb42aa215fa4eadac435596e5d8a55d |
PMID | 35227290 |
PQID | 2634849622 |
PQPubID | 23479 |
PageCount | 15 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_6fb42aa215fa4eadac435596e5d8a55d pubmedcentral_primary_oai_pubmedcentral_nih_gov_8883689 proquest_miscellaneous_2634849622 gale_infotracmisc_A699488383 gale_infotracacademiconefile_A699488383 gale_healthsolutions_A699488383 pubmed_primary_35227290 crossref_primary_10_1186_s13073_022_01029_7 crossref_citationtrail_10_1186_s13073_022_01029_7 springer_journals_10_1186_s13073_022_01029_7 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2022-02-26 |
PublicationDateYYYYMMDD | 2022-02-26 |
PublicationDate_xml | – month: 02 year: 2022 text: 2022-02-26 day: 26 |
PublicationDecade | 2020 |
PublicationPlace | London |
PublicationPlace_xml | – name: London – name: England |
PublicationTitle | Genome medicine |
PublicationTitleAbbrev | Genome Med |
PublicationTitleAlternate | Genome Med |
PublicationYear | 2022 |
Publisher | BioMed Central BioMed Central Ltd BMC |
Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd – name: BMC |
References | Y Jiao (1029_CR39) 2011; 331 Z Yu (1029_CR51) 2019; 18 H Xu (1029_CR48) 2011; 13 M Parker (1029_CR25) 2012; 13 LJ Van’t Veer (1029_CR50) 2002; 415 PJ Campbell (1029_CR20) 2020; 578 FP Barthel (1029_CR27) 2017; 49 TM Bryan (1029_CR10) 1997; 3 1029_CR23 GM Frampton (1029_CR15) 2013; 31 1029_CR22 M Capezzone (1029_CR45) 2008; 93 CM Heaphy (1029_CR13) 2011; 179 JD Henson (1029_CR14) 2010; 584 C-Q Zhu (1029_CR46) 2006; 94 TO Nielsen (1029_CR57) 2020; 00 T Inui (1029_CR35) 2001; 14 N Kim (1029_CR6) 1994; 266 JD Henson (1029_CR11) 2002; 21 AI Idilli (1029_CR31) 2020; 11 T Zhu (1029_CR53) 2020; 106 G Kanyılmaz (1029_CR54) 2019; 15 L Feuerbach (1029_CR18) 2019; 20 K Perrem (1029_CR42) 2001; 21 ARS Gocha (1029_CR44) 2013; 182 D Hanahan (1029_CR1) 2011; 144 F D’Adda Di Fagagna (1029_CR5) 2003; 426 R Rahman (1029_CR3) 2008; 43 X Hua (1029_CR24) 2016; 98 S Deb (1029_CR52) 2014; 110 CM Heaphy (1029_CR12) 2011; 333 ZR Chalmers (1029_CR16) 2017; 9 MA Cerone (1029_CR41) 2001; 10 G Singal (1029_CR21) 2019; 321 KP Porkka (1029_CR33) 2004; 39 G Ciriello (1029_CR37) 2012; 22 R Villa (1029_CR43) 2008; 14 JW Shay (1029_CR4) 2005; 26 JW Shay (1029_CR7) 1997; 33 JM Atienza (1029_CR32) 2005; 4 NA Soliman (1029_CR55) 2016; 13 EH Blackburn (1029_CR9) 1989; 31 Z Deng (1029_CR29) 2012; 31 R Lu (1029_CR40) 2014; 33 T Inui (1029_CR34) 2002; 273 CA Lovejoy (1029_CR28) 2012; 8 RC Ramaker (1029_CR26) 2017; 8 SA Forbes (1029_CR17) 2011; 39 EJ Lee (1029_CR36) 2018; 26 L Sieverling (1029_CR19) 2020; 11 M Yan (1029_CR49) 2012; 14 X Zhu (1029_CR56) 2020; 10 GB Morin (1029_CR8) 1989; 59 C-H Yeang (1029_CR38) 2008; 22 X Yuan (1029_CR47) 2019; 38 MT Hayashi (1029_CR30) 2012; 19 KE Huffman (1029_CR2) 2000; 275 |
References_xml | – volume: 8 start-page: 38668 year: 2017 ident: 1029_CR26 publication-title: Oncotarget. doi: 10.18632/oncotarget.16961 – volume: 3 start-page: 1271 year: 1997 ident: 1029_CR10 publication-title: Nat Med doi: 10.1038/nm1197-1271 – volume: 39 start-page: 945 year: 2011 ident: 1029_CR17 publication-title: Nucleic Acids Res doi: 10.1093/nar/gkq929 – volume: 14 start-page: 275 year: 2001 ident: 1029_CR35 publication-title: Hum Cell – volume: 426 start-page: 194 year: 2003 ident: 1029_CR5 publication-title: Nature. doi: 10.1038/nature02118 – volume: 584 start-page: 3800 year: 2010 ident: 1029_CR14 publication-title: FEBS Lett doi: 10.1016/j.febslet.2010.06.009 – volume: 38 start-page: 6172 year: 2019 ident: 1029_CR47 publication-title: Oncogene doi: 10.1038/s41388-019-0872-9 – volume: 415 start-page: 530 year: 2002 ident: 1029_CR50 publication-title: Nature. doi: 10.1038/415530a – volume: 94 start-page: 1452 year: 2006 ident: 1029_CR46 publication-title: Br J Cancer doi: 10.1038/sj.bjc.6603110 – volume: 331 start-page: 1199 year: 2011 ident: 1029_CR39 publication-title: Science (80- ) doi: 10.1126/science.1200609 – volume: 9 start-page: 34 year: 2017 ident: 1029_CR16 publication-title: Genome Med doi: 10.1186/s13073-017-0424-2 – volume: 10 start-page: 1 year: 2020 ident: 1029_CR56 publication-title: Sci Rep doi: 10.1038/s41598-019-56847-4 – volume: 49 start-page: 349 year: 2017 ident: 1029_CR27 publication-title: Nat Genet doi: 10.1038/ng.3781 – volume: 59 start-page: 521 year: 1989 ident: 1029_CR8 publication-title: Cell. doi: 10.1016/0092-8674(89)90035-4 – volume: 20 start-page: 1 year: 2019 ident: 1029_CR18 publication-title: BMC Bioinformatics doi: 10.1186/s12859-019-2851-0 – volume: 93 start-page: 3950 year: 2008 ident: 1029_CR45 publication-title: J Clin Endocrinol Metab doi: 10.1210/jc.2008-0372 – volume: 33 start-page: 787 year: 1997 ident: 1029_CR7 publication-title: Eur J Cancer doi: 10.1016/S0959-8049(97)00062-2 – ident: 1029_CR22 doi: 10.1111/1475-6773.13669 – volume: 31 start-page: 4165 year: 2012 ident: 1029_CR29 publication-title: EMBO J doi: 10.1038/emboj.2012.266 – volume: 26 start-page: 867 year: 2005 ident: 1029_CR4 publication-title: Carcinogenesis. doi: 10.1093/carcin/bgh296 – volume: 106 start-page: 223 year: 2020 ident: 1029_CR53 publication-title: Tumori. doi: 10.1177/0300891620910805 – volume: 22 start-page: 398 year: 2012 ident: 1029_CR37 publication-title: Genome Res doi: 10.1101/gr.125567.111 – volume: 22 start-page: 2605 year: 2008 ident: 1029_CR38 publication-title: FASEB J doi: 10.1096/fj.08-108985 – volume: 14 start-page: R69 year: 2012 ident: 1029_CR49 publication-title: Breast Cancer Res doi: 10.1186/bcr3176 – volume: 33 start-page: 1495 year: 2014 ident: 1029_CR40 publication-title: Oncogene. doi: 10.1038/onc.2013.103 – volume: 21 start-page: 598 year: 2002 ident: 1029_CR11 publication-title: Oncogene. doi: 10.1038/sj.onc.1205058 – volume: 39 start-page: 1 year: 2004 ident: 1029_CR33 publication-title: Genes Chromosom Cancer doi: 10.1002/gcc.10289 – volume: 273 start-page: 147 year: 2002 ident: 1029_CR34 publication-title: Exp Cell Res doi: 10.1006/excr.2001.5446 – volume: 13 start-page: 496 year: 2016 ident: 1029_CR55 publication-title: Cancer Biol Med doi: 10.20892/j.issn.2095-3941.2016.0066 – volume: 31 start-page: 553 year: 1989 ident: 1029_CR9 publication-title: Genome. doi: 10.1139/g89-104 – volume: 275 start-page: 19719 year: 2000 ident: 1029_CR2 publication-title: J Biol Chem doi: 10.1074/jbc.M002843200 – volume: 13 start-page: R113 year: 2012 ident: 1029_CR25 publication-title: Genome Biol doi: 10.1186/gb-2012-13-12-r113 – volume: 14 start-page: 4134 year: 2008 ident: 1029_CR43 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-08-0099 – volume: 19 start-page: 387 year: 2012 ident: 1029_CR30 publication-title: Nat Struct Mol Biol doi: 10.1038/nsmb.2245 – volume: 26 start-page: 845 year: 2018 ident: 1029_CR36 publication-title: Mol Ther doi: 10.1016/j.ymthe.2017.12.015 – volume: 10 start-page: 1945 year: 2001 ident: 1029_CR41 publication-title: Hum Mol Genet doi: 10.1093/hmg/10.18.1945 – volume: 182 start-page: 41 year: 2013 ident: 1029_CR44 publication-title: Am J Pathol doi: 10.1016/j.ajpath.2012.10.001 – volume: 8 start-page: 12 year: 2012 ident: 1029_CR28 publication-title: PLoS Genet doi: 10.1371/journal.pgen.1002772 – volume: 31 start-page: 1023 year: 2013 ident: 1029_CR15 publication-title: Nat Biotechnol doi: 10.1038/nbt.2696 – volume: 578 start-page: 82 year: 2020 ident: 1029_CR20 publication-title: Nature. doi: 10.1038/s41586-020-1969-6 – volume: 179 start-page: 1608 year: 2011 ident: 1029_CR13 publication-title: Am J Pathol doi: 10.1016/j.ajpath.2011.06.018 – volume: 21 start-page: 3862 year: 2001 ident: 1029_CR42 publication-title: Mol Cell Biol doi: 10.1128/MCB.21.12.3862-3875.2001 – volume: 4 start-page: 361 year: 2005 ident: 1029_CR32 publication-title: Mol Cancer Ther doi: 10.1158/1535-7163.MCT-04-0241 – volume: 00 start-page: 1 year: 2020 ident: 1029_CR57 publication-title: JNCI J Natl Cancer Inst – volume: 18 start-page: 518 year: 2019 ident: 1029_CR51 publication-title: Oncol Lett – volume: 144 start-page: 646 year: 2011 ident: 1029_CR1 publication-title: Cell. doi: 10.1016/j.cell.2011.02.013 – volume: 11 start-page: 1 year: 2020 ident: 1029_CR19 publication-title: Nat Commun doi: 10.1038/s41467-019-13824-9 – volume: 43 start-page: 258 year: 2008 ident: 1029_CR3 publication-title: Exp Gerontol doi: 10.1016/j.exger.2008.01.005 – volume: 321 start-page: 1391 year: 2019 ident: 1029_CR21 publication-title: JAMA. doi: 10.1001/jama.2019.3241 – volume: 110 start-page: 1606 year: 2014 ident: 1029_CR52 publication-title: Br J Cancer doi: 10.1038/bjc.2014.31 – volume: 11 start-page: 1 year: 2020 ident: 1029_CR31 publication-title: Genes (Basel) doi: 10.3390/genes11121442 – volume: 333 start-page: 425 year: 2011 ident: 1029_CR12 publication-title: Science. doi: 10.1126/science.1207313 – volume: 13 start-page: R9 year: 2011 ident: 1029_CR48 publication-title: Breast Cancer Res doi: 10.1186/bcr2814 – volume: 98 start-page: 442 year: 2016 ident: 1029_CR24 publication-title: Am J Hum Genet doi: 10.1016/j.ajhg.2015.12.021 – volume: 15 start-page: 256 year: 2019 ident: 1029_CR54 publication-title: Eur J Breast Heal doi: 10.5152/ejbh.2019.4778 – ident: 1029_CR23 – volume: 266 start-page: 2011 year: 1994 ident: 1029_CR6 publication-title: Science (80- ) doi: 10.1126/science.7605428 |
SSID | ssj0064247 |
Score | 2.312926 |
Snippet | Background
Cancer cells can proliferate indefinitely through telomere maintenance mechanisms. These mechanisms include telomerase-dependent elongation,... Cancer cells can proliferate indefinitely through telomere maintenance mechanisms. These mechanisms include telomerase-dependent elongation, mediated by TERT... Background Cancer cells can proliferate indefinitely through telomere maintenance mechanisms. These mechanisms include telomerase-dependent elongation,... Abstract Background Cancer cells can proliferate indefinitely through telomere maintenance mechanisms. These mechanisms include telomerase-dependent... |
SourceID | doaj pubmedcentral proquest gale pubmed crossref springer |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 25 |
SubjectTerms | Analysis Bioinformatics Biomedical and Life Sciences Biomedicine Breast Cancer Cancer Research Cell Cycle Proteins - genetics DNA-Binding Proteins - genetics Genes Hepatocyte Growth Factor - genetics Hepatocyte Growth Factor - metabolism HGF Human Genetics Humans Medicine/Public Health Metabolomics Neoplasms - genetics RAD21 Systems Biology Telomerase Telomerase - genetics Telomere Telomere - genetics Telomere Homeostasis Telomeres TERC Tumor X-linked Nuclear Protein - genetics |
SummonAdditionalLinks | – databaseName: Springer Nature OA Free Journals dbid: C6C link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1bi9QwFA66Ivgi3q2uGkHwQYNNJkmTx3F0HAR9EBf2LaRpyghDK9MO4r_3nLQdtqss-NqcXpJzyZfmnC-EvIrcR1_mhoXaKybtQjNfCs1iHpDACgB6xHrnL1_15kx-PlfnI00O1sJc3L_nRr_rOBohw5xzZD-zrLhObii4iNa80qsp6gKMlsVUFPPP-2YTT-Ln_zsKX5iGLqdIXtonTdPP-g65PeJGuhwUfZdci809cnM4SfL3fXJYUnBrFlCHe5rqdzGzibY17eOuTdsyFNPS4UW027a_OtpvfU-_LT8ITkGcbj6tado6H37hUb-P1I-6ixXF_7V01-KnTU-M3QNytv74fbVh44kKLABM6hlM7roS0UsepK9KWRlrQDVBcuipCdZUPpaVlzYW4JgQBnNljBWxDLUqkcX2ITlp2iY-JlTlwfJQ1FJ7AAWVNl4aXtcqXxQLVZc8I3wabhdGunE89WLn0rLDaDeoyIGKXFKRKzLy5njPz4Fs40rp96jFoyQSZacLYD9u9Dun61IK7wHY1F6C1_gA-FBZHVVlvFJVRl6gDbih6vTo7m6prYXYBuv3jLxOEujw0IHgx7oFGAakzppJns4kwVHDrPnlZGcOmzC7rYntoXNCL6SRVguRkUeD3R17hQAZFkB5RoqZRc66PW9pfmwTT7iB12pjM_J2sl03BqjuimF98n_iT8ktkbxMMKFPyUm_P8RngNP68nly0D-SoTRu priority: 102 providerName: Springer Nature |
Title | A pan-cancer landscape of telomeric content shows that RAD21 and HGF alterations are associated with longer telomeres |
URI | https://link.springer.com/article/10.1186/s13073-022-01029-7 https://www.ncbi.nlm.nih.gov/pubmed/35227290 https://www.proquest.com/docview/2634849622 https://pubmed.ncbi.nlm.nih.gov/PMC8883689 https://doaj.org/article/6fb42aa215fa4eadac435596e5d8a55d |
Volume | 14 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3di9QwEA96Ivgifls91wiCDxquzSZp8ri33t4ieMjhwb6FNE1ZYdnKtov43zuTtsv1hPPFl4VuZredzGeamV8IeR8yF1yRauYrJ5kwU8VcwRULqUcAK0jQA_Y7f71QyyvxZSVX1476wpqwDh64m7gTVRWCOweRqXIC2HYeArw0KshSOylL9L6pSYfFVOeDIakW-dAio9VJk6EqM6xcRww1w_JRGIpo_X_75GtB6WbB5I1d0xiMFo_Iwz6LpLPu6R-TO2H7hNzvzpX8_ZTsZxSMnHmU6I7Gbl6sc6J1RduwqeMmDcUidbgRbdb1r4a2a9fSy9lnnlEgp8vzBY0b6d0LPep2gbpekqGk-PaWbmp8tOEfQ_OMXC3Ovs-XrD9fgXlImloGoV6VPDiReeHKQpTaaBCUFxlwqr3RpQtF6YQJOZgpOMVUam14KHwlC8S0fU6OtvU2vCRUpt5kPq-EcpAilEo7obOqkuk0n8qqyBKSDdNtfQ8-jmdgbGxchGhlOxFZEJGNIrJ5Qj4efvOzg964lfoUpXigRNjs-AUok-2Vyf5LmRLyFnXAdj2oB-O3M2UMeDpYzSfkQ6RA8wcGvOu7GGAaEEhrRHk8ogSz9aPhd4OeWRzCWrdtqPeN5WoqtDCK84S86PTuwBWmy7AcShOSjzRyxPZ4ZPtjHVHDNdxWaZOQT4Pu2t5dNbdM66v_Ma2vyQMebY8zro7JUbvbhzeQy7XFhNzNV_mE3Ds9u_h2CVdzNZ9EU4bP81X2B2uBSaI |
linkProvider | Directory of Open Access Journals |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3db9MwELdgCMEL4pvAYEZC4gGsJa7t2I-lUApse0CbtDfLcRwVqWqmJtXEf8-dk1TLQJN4jc9J7Pvw2Xf3MyHvQuaCK1LNfOUkE2aimCu4YiH1CGAFDnrAeufjE7U4E9_P5XkPk4O1MFfj95lWh02GQsgw5xzRzwzLb5M7GLlEnPyZmg1WF9xokQ9FMf_sN1p4Ij7_31b4yjJ0PUXyWpw0Lj_zh-RB7zfSacfoR-RWWD8md7ubJH8_IdspBbVmHnm4obF-FzObaF3RNqzqGJahmJYOH6LNsr5saLt0Lf05_cwzCuR08XVOY-i8O8KjbhOo63kXSorntXRV468NbwzNU3I2_3I6W7D-RgXmwU1qGSzuquTBicwLVxai1EYDa7zIYKTaG126UJROmJCDYoIZTKXWhofCV7JAFNtnZG9dr8MLQmXqTebzSigHTkGptBM6qyqZTvKJrIosIdkw3db3cON468XKxm2HVrZjkQUW2cgimyfkw67PRQe2cSP1J-TijhKBsuMDkB_b651VVSG4c-DYVE6A1jgP_qE0KshSOynLhBygDNiu6nSn7naqjAHbBvv3hLyPFKjwMADv-roFmAaEzhpR7o8oQVH9qPntIGcWmzC7bR3qbWO5mggtjOI8Ic87uduNCh1k2AClCclHEjka9rhl_WsZccI1fFZpk5CPg-za3kA1N0zry_8jPyD3FqfHR_bo28mPV-Q-jxrHGVf7ZK_dbMNr8Nna4k1U1j881jdd |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3db9MwELdgCMQL4nMEBjMSEg9gLXFtx34sHaV8TQgxaW-W4zgUqWqmJhXiv-fOSaploEm81pe25_vwz_Hdz4S8DJkLrkg185WTTJiJYq7gioXUI4EVAPSA_c5fTtTiVHw8k2cXuvhjtftwJNn1NCBL07o9Oi-rLsS1OmoydE2GlejIiWZYfp3cQK4uLOqbqdmQiwFci3xolfnnc6PlKLL2_52bLyxOlwsnL52exkVpfpfc6dEknXbmv0euhfV9crO7X_L3A7KdUgh25tGyGxq7erHeidYVbcOqjoc1tNecNsv6V0PbpWvpt-kxzyiI08X7OY0H6t2LPeo2gbreoqGk-BaXrmr8a8M3huYhOZ2_-z5bsP6eBeYBPLUMlnxV8uBE5oUrC1Fqo8FgXmSgqfZGly4UpRMm5BCukBxTqbXhofCVLJDb9hHZW9fr8JhQmXqT-bwSygFUKJV2QmdVJdNJPpFVkSUkG6bb-p6EHO_CWNm4GdHKdiayYCIbTWTzhLzePXPeUXBcKf0WrbiTRPrs-EG9-WH7aLSqKgR3DuBO5QTEkvOAGqVRQZbaSVkm5BB9wHa9qLskYKfKGMh4sKtPyKsogWkAFPCu72aAaUBCrZHkwUgSwtePhl8MfmZxCGve1qHeNparidDCKM4Tst_53U4rhM2wLUoTko88cqT2eGT9cxnZwzX8rNImIW8G37V92mqumNYn_yd-SG59PZ7bzx9OPj0lt3kMOM64OiB77WYbngGQa4vnMVb_ADlgP60 |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+pan-cancer+landscape+of+telomeric+content+shows+that+RAD21+and+HGF+alterations+are+associated+with+longer+telomeres&rft.jtitle=Genome+medicine&rft.au=Sharaf%2C+Radwa&rft.au=Montesion%2C+Meagan&rft.au=Hopkins%2C+Julia+F.&rft.au=Song%2C+Jiarong&rft.date=2022-02-26&rft.issn=1756-994X&rft.eissn=1756-994X&rft.volume=14&rft.issue=1&rft_id=info:doi/10.1186%2Fs13073-022-01029-7&rft.externalDBID=n%2Fa&rft.externalDocID=10_1186_s13073_022_01029_7 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1756-994X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1756-994X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1756-994X&client=summon |